Compare FRHC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRHC | GKOS |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.9B |
| IPO Year | 1996 | 2015 |
| Metric | FRHC | GKOS |
|---|---|---|
| Price | $133.87 | $97.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $133.07 |
| AVG Volume (30 Days) | 93.5K | ★ 679.7K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $2,050,527,000.00 | $507,442,000.00 |
| Revenue This Year | N/A | $23.39 |
| Revenue Next Year | N/A | $27.46 |
| P/E Ratio | $57.65 | ★ N/A |
| Revenue Growth | 25.41 | ★ 32.33 |
| 52 Week Low | $107.98 | $73.16 |
| 52 Week High | $194.01 | $130.23 |
| Indicator | FRHC | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 62.93 | 29.36 |
| Support Level | $130.02 | $81.54 |
| Resistance Level | $138.47 | $102.19 |
| Average True Range (ATR) | 5.03 | 3.58 |
| MACD | 1.81 | -2.20 |
| Stochastic Oscillator | 82.88 | 0.38 |
Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.